NURIX THERAPEUTICS, INC. Research and Development Expense
NURIX THERAPEUTICS, INC. (NRIX) reported Research and Development Expense of $87.65 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. research and development expense for the quarter ending 2026-05-31 was $87.65M, a 12.24% increase year-over-year.
- NURIX THERAPEUTICS, INC. research and development expense for the quarter ending 2026-02-28 was $84.14M, a 20.78% increase year-over-year.
- NURIX THERAPEUTICS, INC. research and development expense for the quarter ending 2025-11-30 was $83.02M, a 23.50% increase year-over-year.
- NURIX THERAPEUTICS, INC. research and development expense for the quarter ending 2025-08-31 was $86.12M, a 55.22% increase year-over-year.
- NURIX THERAPEUTICS, INC. research and development expense for fiscal 2025 was $316.90M, a 42.99% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. research and development expense for fiscal 2024 was $221.63M, a 17.17% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. research and development expense for fiscal 2023 was $189.15M, a 2.52% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. research and development expense for fiscal 2022 was $184.50M, a 58.46% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $87.65M 10-Q · filed 2026-07-09 | $171.79M 10-Q · filed 2026-07-09 | $254.81M derived: sum of 3 quarters · filed 2026-07-09 | $340.93M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $84.14M 10-Q · filed 2026-04-08 | $167.16M derived: sum of 2 quarters · filed 2026-04-08 | $253.28M derived: sum of 3 quarters · filed 2026-04-08 | $331.38M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $83.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $169.14M derived: sum of 2 quarters · filed 2026-01-28 | $247.24M derived: sum of 3 quarters · filed 2026-07-09 | $316.90M 10-K · filed 2026-01-28 |
| 2025-08-31 | $86.12M 10-Q · filed 2025-10-09 | $164.22M derived: sum of 2 quarters · filed 2026-07-09 | $233.88M 10-Q · filed 2025-10-09 | $301.10M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $78.10M 10-Q · filed 2026-07-09 | $147.76M 10-Q · filed 2026-07-09 | $214.98M derived: sum of 3 quarters · filed 2026-07-09 | $270.46M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $69.66M 10-Q · filed 2026-04-08 | $136.89M derived: sum of 2 quarters · filed 2026-04-08 | $192.37M derived: sum of 3 quarters · filed 2026-04-08 | $241.29M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $67.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $122.70M derived: sum of 2 quarters · filed 2026-01-28 | $171.63M derived: sum of 3 quarters · filed 2026-01-28 | $221.63M 10-K · filed 2026-01-28 |
| 2024-08-31 | $55.48M 10-Q · filed 2025-10-09 | $104.40M derived: sum of 2 quarters · filed 2025-10-09 | $154.41M 10-Q · filed 2025-10-09 | $204.12M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $48.92M 10-Q · filed 2025-07-09 | $98.93M 10-Q · filed 2025-07-09 | $148.64M derived: sum of 3 quarters · filed 2026-01-28 | $196.50M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $50.01M 10-Q · filed 2025-04-08 | $99.72M derived: sum of 2 quarters · filed 2026-01-28 | $147.57M derived: sum of 3 quarters · filed 2026-01-28 | $193.34M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $49.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $97.57M derived: sum of 2 quarters · filed 2026-01-28 | $143.33M derived: sum of 3 quarters · filed 2026-01-28 | $189.15M 10-K · filed 2026-01-28 |
| 2023-08-31 | $47.86M 10-Q · filed 2024-10-11 | $93.62M derived: sum of 2 quarters · filed 2024-10-11 | $139.44M 10-Q · filed 2024-10-11 | $185.54M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $45.76M 10-Q · filed 2024-07-11 | $91.58M 10-Q · filed 2024-07-11 | $137.69M derived: sum of 3 quarters · filed 2025-01-28 | $185.45M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $45.82M 10-Q · filed 2024-04-10 | $91.92M derived: sum of 2 quarters · filed 2025-01-28 | $139.68M derived: sum of 3 quarters · filed 2025-01-28 | $187.18M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $46.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $93.87M derived: sum of 2 quarters · filed 2025-01-28 | $141.36M derived: sum of 3 quarters · filed 2025-01-28 | $184.50M 10-K · filed 2025-01-28 |
| 2022-08-31 | $47.76M 10-Q · filed 2023-10-12 | $95.25M derived: sum of 2 quarters · filed 2023-10-12 | $138.39M 10-Q · filed 2023-10-12 | $174.92M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $47.49M 10-Q · filed 2023-07-13 | $90.63M 10-Q · filed 2023-07-13 | $127.16M derived: sum of 3 quarters · filed 2023-07-13 | $158.07M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $43.14M 10-Q · filed 2023-04-13 | $79.67M derived: sum of 2 quarters · filed 2023-04-13 | $110.57M derived: sum of 3 quarters · filed 2023-04-13 | $136.57M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $36.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $67.44M derived: sum of 2 quarters · filed 2023-02-09 | $93.43M derived: sum of 3 quarters · filed 2023-02-09 | $116.43M 10-K · filed 2023-02-09 |
| 2021-08-31 | $30.91M 10-Q · filed 2022-10-06 | $56.90M derived: sum of 2 quarters · filed 2022-10-06 | $79.90M 10-Q · filed 2022-10-06 | $100.35M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $25.99M 10-Q · filed 2022-07-07 | $49.00M 10-Q · filed 2022-07-07 | $69.44M derived: sum of 3 quarters · filed 2022-07-07 | $88.38M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $23.00M 10-Q · filed 2022-04-08 | $43.45M derived: sum of 2 quarters · filed 2022-04-08 | $62.39M derived: sum of 3 quarters · filed 2022-04-08 | $76.53M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $20.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $39.38M derived: sum of 2 quarters · filed 2022-01-28 | $53.53M derived: sum of 3 quarters · filed 2022-01-28 | $66.49M 10-K · filed 2022-01-28 |
| 2020-08-31 | $18.94M 10-Q · filed 2021-10-14 | $33.08M derived: sum of 2 quarters · filed 2021-10-14 | $46.05M 10-Q · filed 2021-10-14 | $58.87M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $14.14M 10-Q · filed 2021-07-13 | $27.11M 10-Q · filed 2021-07-13 | $39.93M derived: sum of 3 quarters · filed 2022-01-28 | $50.94M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-02-29 | $12.97M 10-Q · filed 2021-04-13 | $25.79M derived: sum of 2 quarters · filed 2022-01-28 | $36.80M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2019-11-30 | $12.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $23.83M derived: sum of 2 quarters · filed 2022-01-28 | $45.02M 10-K · filed 2022-01-28 | |
| 2019-08-31 | $11.01M 10-Q · filed 2020-10-14 | $32.20M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |